Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 7, Issue 2, Pages 227-241Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.10.98
Keywords
apoA-1; atherosclerosis; HMG-CoA reductase inhibitors; homocysteine; oxidized LDL; proinflammatory HDL; statins; systemic lupus erythematosus
Categories
Funding
- Arthritis Foundation
- NIH/NIAMS [1K23AR053864-01A1]
- Rheuminations
Ask authors/readers for more resources
Patients with systemic lupus erythematosus have a significantly increased risk of cardiovascular events due to atherosclerosis. Traditional cardiac risk factors cannot fully explain this increased risk. Recent evidence strongly suggests that atherosclerotic plaque is largely driven by inflammation and an active immunological response, in contrast to the long-held belief that plaque is a passive accumulation of lipids in the arterial wall. Current approaches to the prevention of atherosclerosis in systemic lupus erythematosus involve targeting modifiable cardiac risk factors. Future preventive strategies may include therapies that counteract the immunologic responses that lead to plaque formation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available